15 December 2022  
EMA/CHMP/916000/2022  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Triumeq 
dolutegravir / abacavir / lamivudine 
On 15 December 2022, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion recommending a change to the terms of the marketing authorisation for the medicinal product 
Triumeq. The marketing authorisation holder for this medicinal product is ViiV Healthcare B.V. 
The CHMP adopted the addition of a new pharmaceutical form (dispersible tablets) associated with a new 
strength (5 mg dolutegravir, 60 mg abacavir, and 30 mg lamivudine) suitable for children weighing from 
14 to 25 kg. For information, the full indication for dispersible tablets will be as follows:2 
Triumeq is indicated for the treatment of Human Immunodeficiency Virus (HIV) 
infected children weighing at least 14 kg to less than 25 kg. 
Before initiating treatment with abacavir-containing products, screening for carriage 
of the HLA-B*5701 allele should be performed in any HIV-infected patient, 
irrespective of racial origin. Abacavir should not be used in patients known to carry 
the HLA-B*5701 allele. 
The CHMP also adopted an extension to the indication for the film-coated tablets form to include 
treatment of children weighing at least 25 kg. For information, the full indication for film-coated tablets 
will be as follows:2 
Triumeq is indicated for the treatment of Human Immunodeficiency Virus (HIV) infected adults, 
and adolescents and children above 12 years of age weighing at least 25 40 kg. 
Before initiating treatment with abacavir-containing products, screening for carriage of the HLA-
B*5701 allele should be performed in any HIV-infected patient, irrespective of racial origin. 
Abacavir should not be used in patients known to carry the HLA-B*5701 allele. 
Detailed recommendations for the use of this product will be described in the updated summary of 
product characteristics (SmPC), which will be published in the revised European public assessment report 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
2 New text in bold, removed text as strikethrough 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union   
© European Medicines Agency, 2022. Reproduction is authorised provided the source is acknowledged. 
 
 
 
 
 
 
 
(EPAR), and will be available in all official European Union languages after a decision on this change to 
the marketing authorisation has been granted by the European Commission. 
Triumeq  
EMA/CHMP/916000/2022 
Page 2/2 
 
 
 
